Real‐World Clinical Practice of Lecanemab at PUMCH: Focus on Dynamic Imaging and Biomarker Evolution

Abstract

Background: Lecanemab was widely used in China since June 2024 . Its real‐world efficacy and safety profile have attracted significant attention. The aim of the study is to evaluate the clinical outcomes, adverse effects, and dynamic follow‐up results of lecanemab in a Chinese population.

The paper